ProCE Banner Activity

Considering the Role of MRD Evaluation for Patients With CLL

Clinical Thought
The implications of minimal residual disease status on treatment of CLL is evolving. Here’s my take on what you should know now.

Released: September 29, 2020

Expiration: September 28, 2021

No longer available for credit.

Share

Faculty

Danielle M. Brander

Danielle M. Brander, MD

Medical Instructor
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Danielle M. Brander, MD

Medical Instructor
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Danielle M. Brander, MD, has disclosed that she has received consulting fees from AbbVie, ArQule, AstraZeneca, Genentech, Pfizer, Pharmacyclics, Teva, TG Therapeutics, and Verastem and funds for research support paid to her institution from AbbVie; ArQule; Ascentage; AstraZeneca; BeiGene; DTRM; Genentech; Juno Therapeutics, a Bristol-Myers Squibb company; MEI Pharma; Pharmacyclics; TG Therapeutics; Tolero; and Verastem.